Exelixis To Expand Prostate Cancer Cohort Of Cabometyx Study
Zacks Investment Research | Jan 07, 2020 10:13PM ET
Exelixis, Inc. (NASDAQ:EXEL) announced that it plans to further expand the metastatic castration-resistant prostate cancer (CRPC) cohort of the phase Ib study, COSMIC-021.
The trial is evaluating the combination of lead drug Cabometyx and Roche’s (OTC:RHHBY) Tecentriq in patients with locally advanced or metastatic solid tumors.
The decision to expand the cohort was based on continued encouraging efficacy and safety data. The cohort, which was previously expanded from 30 to 80 patients in July 2019, will now include up to 130 patients.
The expansion of the cohort by an additional 50 patients will enable Exelixis to further document how the combination will benefit this patient population, as the company is evaluating its potential regulatory plans for the combination and preparing to initiate a phase III study. An additional 50 patients with metastatic CRPC (130 total), who have histologically or cytologically confirmed adenocarcinoma of the prostate, are being enrolled in the study.
We note that COSMIC-021 is a multicenter, phase Ib, open-label study that is divided into two parts — a dose-escalation phase and an expansion cohort phase. The dose-escalation phase of the study determined the optimal dose of Cabometyx to be 40 mg daily when given in combination with Tecentriq (1200 mg infusion once every 3 weeks). The study includes 24 cohorts and aims to enroll up to 1,732 patients with advanced or metastatic solid tumors, including CRPC, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), colorectal cancer, ovarian cancer and urothelial carcinoma (UC), among others. The primary objective in the expansion stage of this trial is to determine the objective response rate in each cohort.
The company’s shares have lost 19.8% in the past year compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.